4.7 Article

Restoring Mood Balance in Depression: Ketamine Reverses Deficit in Dopamine-Dependent Synaptic Plasticity

Journal

BIOLOGICAL PSYCHIATRY
Volume 76, Issue 12, Pages 927-936

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2014.04.014

Keywords

Dopamine; ketamine; learned helplessness; nucleus accumbens; synaptic plasticity; ventral tegmental area

Funding

  1. National Alliance for Research on Schizophrenia and Depression-The Brain and Behavior Research Foundation
  2. United States Public Health Service [MH57440, MH191180]
  3. Johnson and Johnson
  4. Lundbeck
  5. Pfizer
  6. GlaxoSmithKline
  7. Puretech Ventures
  8. Merck
  9. Takeda
  10. Dainippon Sumitomo
  11. Otsuka
  12. Eli Lilly and Co.
  13. Roche
  14. Asubio

Ask authors/readers for more resources

Background: One of the most novel and exciting findings in major depressive disorder research over the last decade is the discovery of the fast-acting and long-lasting antidepressant effects of ketamine. Indeed, the therapeutic effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month or longer to be expressed, with about a third of major depressive disorder patients resistant to treatment. Clinical studies have shown that a low dose of ketamine exhibits fast-acting relatively sustained antidepressant action, even in treatment-resistant patients. However, the mechanisms of ketamine action at a systems level remain unclear. Methods: Wistar-Kyoto rats were exposed to inescapable, uncontrollable footshocks. To evaluate learned helplessness behavior, we used an active avoidance task in a shuttle box equipped with an electrical grid floor. After helplessness assessment, we performed in vivo electrophysiological recordings first from ventral tegmental area dopaminergic (DA) neurons and second from accumbens neurons responsive to fimbria stimulation. Ketamine was injected and tested on helpless behavior and electrophysiological recordings. Results: We show that ketamine is able to restore the integrity of a network by acting on the DA system and restoring synaptic dysfunction observed in stress-induced depression. We show that part of the antidepressant effect of ketamine is via the DA system. Indeed, injection of ketamine restores a decreased dopamine neuron population activity, as well as synaptic plasticity (long-term potentiation) in the hippocampus-accumbens pathway, via, in part, activation of D1 receptors. Conclusions: This work provides a unique systems perspective on the mechanisms of ketamine on a disrupted limbic system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available